Stoke Therapeutics (STOK) Enterprise Value (2018 - 2026)
Stoke Therapeutics' quarterly Enterprise Value came in at -$343.5 million in Q1 2026, up 3.86% year-on-year from -$330.8 million in Q1 2025, and down 20.68% quarter-over-quarter from -$284.7 million in Q4 2025.
Stoke Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$343.5 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 3.86% year-over-year to -$343.5 million; the trailing twelve-month figure through Mar 2026 stood at -$343.5 million (up 3.86% YoY), and the FY2025 full-year result was -$284.7 million, down 31.25% from the prior year.
- Enterprise Value for Q1 2026 stood at -$343.5 million, down from -$284.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$83.4 million in Q3 2025, with the low at -$357.3 million in Q1 2025.
- Average Enterprise Value over 5 years is -$227.1 million, with a median of -$229.6 million recorded in 2022.
- Peak annual rise in Enterprise Value reached 47.53% in 2025, while the deepest fall reached 100.09% in 2025.
- Tracing STOK's Enterprise Value over 5 years: stood at -$229.6 million in 2022, then advanced by 12.28% to -$201.4 million in 2023, then decreased by 7.7% to -$216.9 million in 2024, then plunged by 31.25% to -$284.7 million in 2025, then dropped by 20.68% to -$343.5 million in 2026.
- The last three Enterprise Value figures came in at -$343.5 million (Q1 2026), -$284.7 million (Q4 2025), and -$83.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -343.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -343.55 Mn |
| Dec 31, 2025 | -284.67 Mn |
| Sep 30, 2025 | -83.39 Mn |
| Jun 30, 2025 | -101.55 Mn |
| Mar 31, 2025 | -357.32 Mn |
| Dec 31, 2024 | -216.90 Mn |
| Sep 30, 2024 | -150.09 Mn |
| Jun 30, 2024 | -193.55 Mn |
| Mar 31, 2024 | -178.58 Mn |
| Dec 31, 2023 | -201.39 Mn |
| Sep 30, 2023 | -214.72 Mn |
| Jun 30, 2023 | -231.45 Mn |
| Mar 31, 2023 | -253.67 Mn |
| Dec 31, 2022 | -229.60 Mn |
| Sep 30, 2022 | -251.66 Mn |
| Jun 30, 2022 | -275.63 Mn |
| Mar 31, 2022 | -293.22 Mn |
| Dec 31, 2021 | -219.81 Mn |
| Sep 30, 2021 | -149.19 Mn |
| Jun 30, 2021 | -251.23 Mn |
| Mar 31, 2021 | -267.66 Mn |
| Dec 31, 2020 | -287.31 Mn |
| Sep 30, 2020 | -191.46 Mn |
| Jun 30, 2020 | -201.93 Mn |
| Mar 31, 2020 | -211.29 Mn |
| Dec 31, 2019 | -222.47 Mn |
| Sep 30, 2019 | -233.05 Mn |
| Jun 30, 2019 | -242.68 Mn |
| Mar 31, 2019 | -98.65 Mn |
| Dec 31, 2018 | -105.40 Mn |
| Sep 30, 2018 | -19.37 Mn |
| Jun 30, 2018 | -9.55 Mn |